Introduction
============

Haemodilution always occurs during cardiac surgery with cardiopulmonary bypass (CPB). Haemodilution reduces blood viscosity and vascular resistance, and may increase large vessel blood flow maintaining whole body oxygen delivery \[[@B1]\]. It appears that the microcirculation can regulate red cell flow and concentration over a wide range of haematocrit (Hct) levels. Hepatic hypoperfusion and ischaemia are rare but severe complications after coronary artery bypass grafting (CABG) \[[@B2]\]. The incidence of hepatic hypoperfusion leading to surgical interventions ranged between 0.2% and 2% in previous investigations \[[@B3]\]. In these patients mortality rises as high as 60% \[[@B3]\]. Inadequate perfusion and oxygenation of the hepatosplachnic system seems to damage the mucosa of the intestine before any other tissue is compromised \[[@B4]\]. There is growing evidence that even transient hepatic hypoperfusion can lead to severe postoperative complications and affect outcome \[[@B5]\]. Immunological cascades resulting in immune paralysis, sepsis and death are thought to be responsible for this negative impact \[[@B5]-[@B9]\]. Hepatic hypoperfusion resulting in a decrease in hepatic oxygen delivery seems to be one of the key factors of developing multi-organ dysfunction syndrome \[[@B10],[@B11]\]. Therefore, interest is increasing in monitoring hepatic perfusion in the context of haemodilution in cardiac surgical patients. However, detection of hepatic hypoperfusion is challenging, because there are only a few practicable devices available to gather bedside information in a short period of time. This is, however, crucial as hepatic perfusion and oxygenation is compromised before any systemic sign of hypoperfusion is detected \[[@B12]\]. As standard liver function tests are neither sensitive nor specific to identify patients at risk, a major problem is the early recognition of patients with impaired hepatic function \[[@B13]\]. Therefore, hepatic hypoperfusion and hepatic dysfunction remain disguised for too long in a considerable number of patients. Correction of regional oxygenation and perfusion might be of pivotal relevance to reduce endothelial damage and ischaemia-reperfusion episodes and thus might lower the risk of multi-organ dysfunction syndrome after CPB.

The recent introduction of a new non-invasive method to measure indocyanine green (ICG) plasma disappearance rate (PDR) using pulse densitometry offers an opportunity for the early diagnosis of hepatic dysfunction. Clinical data has validated PDR ICG as a marker of hepatic function and perfusion \[[@B14]\]. Previous studies detected a strong association between PDR ICG and outcome in critically ill patients \[[@B15]\]. Recent data from our group showed that in uncomplicated CABG surgery PDR ICG increases after CPB \[[@B16]\]. Persistent low PDR ICG after surgery might be a hint for impaired hepatic perfusion and might influence outcome. Recently, our group undertook a prospective, randomised and controlled study to investigate oxygen delivery and consumption and the clinical outcome of patients who were randomly allocated to one of two Hct groups (20% or 25%) during normothermic CPB \[[@B17]\]. We report here data from this study regarding hepatic function and perfusion.

The primary aim of this analysis was to investigate hepatic function and perfusion by the time course of the PDR ICG and conventional liver enzymes in different groups of haemodilutional anaemia during CPB in elective CABG surgery. The secondary aim was to assess the predictive capacity of these *a priori*chosen parameters for prolonged intensive care unit (ICU) treatment (≥ 48 hours).

Materials and methods
=====================

Patients
--------

After institutional approval by the local ethics committee and preoperative written informed consent, 60 patients undergoing elective CABG surgery were considered eligible for this randomised, controlled clinical trial \[[@B17]\]. Randomisation was performed by a computer-generated random list. One patient had to be excluded from analysis as the autologous blood showed multiple clots after CPB and could not be retransfused. Fifty-nine patients, 30 patients in the 25%-Hct group and 29 patients in the 20%-Hct group, remained for statistical analysis.

Investigational program
-----------------------

Diagnosis, surgery and length of ICU stay were documented for each patient. Vital signs, routine laboratory parameter and complications were recorded on a daily basis. Measurements of the plasma disappearance rate of ICG were performed immediately after induction of anaesthesia, on admission to the ICU, six hours after admission to the ICU and on the first postoperative day. For each measurement, 0.5 mg/kg body weight ICG (Pulsion Medical AG, Munich, Germany) was injected into a central vein. The pulse densitrometric dye decay was analyzed with a commercially available monitor (LiMON-Pulsion Medical AG, Munich, Germany). Each measurement was recorded on a laptop. At the same time points, blood for the analysis of the aspartate aminotransferase (ASAT) and the α-glutathione S-transferase (α-GST) was drawn. For determination of the plasma level of the ASAT and the α-GST 2.7 mL blood was withdrawn. Blood for ASAT was analysed on a commercial laboratory analyser (MODULAR^®^Analytics D2400, P800, Roche, Germany). The level of α-GST was analysed by enzyme immune assay (Biotrin, Herpkit^®^-Á-GST, Dublin, Ireland) according to the manufacturer\'s instructions. The team treating the patient in the operating theatre and in the ICU was blinded to the ICG PDR measurements and to the assignment to a haemodilution group to avoid bias.

Anaesthesia management
----------------------

After oral premedication with midazolam at 0.1 mg/kg body weight general anaesthesia was introduced in all patients. Intravenous induction was performed with etomidate (0.2 mg/kg) and 5 μg/kg fentanyl, 0.1 mg/kg pancuronium, followed by a continuous infusion of 5 to 10 μg/kg/h fentanyl, repetition boluses of 0.1 mg/kg midazolam and 0.03 mg/kg pancuronium before the start of CPB. Anaesthesia was maintained with 0.6 to 1% of end-tidal volume isoflurane. All patients were ventilated with an oxygen-air mixture (fraction of inspired oxygen (FiO~2~) 0.5) to maintain an end-tidal partial pressure of carbon dioxide (pCO~2~) of 35 to 45 mmHg. Before induction of anaesthesia, haemodynamic monitoring was established with a radial artery catheter for invasive blood pressure monitoring, arterial blood gas sampling and haemoglobin determinations. Heart rate, arterial blood pressure (systolic and diastolic) and central venous pressure were continuously monitored and recorded (Solar 8000; Marquette Hellige, Freiburg, Germany). Arterial oxygen saturation was continuously monitored by pulse oximetry. FiO~2~and end-tidal isoflurane concentration, as well as end-tidal pCO~2~, were measured (Solar 8000). Additional monitoring in all patients included oesophageal temperature and tidal volume measurements. After orotracheal intubation, a four-lumen central venous catheter (Arrow, Reading, PA, USA) and an introducer sheath for a thermodilution pulmonary artery catheter (8.5 Fr; Arrow, Reading, PA, USA) were inserted routinely into the right internal jugular vein.

Haemodilution and cardiopulmonary bypass management
---------------------------------------------------

Before institution of CPB isovolaemic haemodilution using a hydroxyethylstarch solution 130/0,4 (Voluven^®^, Fresenius-Kabi, Bad Homburg, Germany) was performed to reduce the Hct to a level of 5 ± 1% above the target Hct-level of 20 ± 1% or 25 ± 1%, respectively. For all measurement of Hct and blood lactate, a blood gas analyser (ABL-700 series, Radiometer, Copenhagen, Denmark) was used. This isovolaemic haemodilution was targeted to a Hct level of 20% during CPB in one group of patients and 25% during CPB in the other group of patients.

After sternotomy aprotinin was applied at a dose of 1.5 × 10^6^IU (total dose of aprotinin was 50.000 KIU/kg bodyweight including the priming of the CPB). Prior to CPB, 400 U/kg heparin (Liquemin^®^Hoffmann-La-Roche, Grenzach-Wyhlen, Switzerland) and additional boluses of 50 U/kg were given if necessary to maintain an activated clotting time of at least 480 seconds. Routine CPB priming included HES 10%, balanced electrolyte solution and heparin (8000 U). CPB was performed under normothermic conditions (blood temperature \> 35.0°C) using a membrane oxygenator and centrifugal pump flows adjusted to the calculated cardiac index of 2.5 l/min/m^2^. Warm intermittent antegrade blood cardioplegia was used.

Prediction of prolonged ICU treatment
-------------------------------------

According to routine clinical practice, all patients are generally transferred from the ICU the day after surgery, if they fulfill the discharge criteria according to standard operating procedures of our department. On average, patients are treated in our department for two days in the ICU \[[@B18]\]. Prolonged ICU treatment was therefore defined as treatment for 48 hours or more. *A priori*we chose age, body mass index (BMI), surgery-related data, group assignment for haemodilutional anaemia and liver perfusion/function parameters to be tested for the ability to predict prolonged ICU treatment.

ICU treatment/discharge criteria
--------------------------------

Indication for ICU treatment in this study was given in all cases of organ dysfunction that were potentially life-threatening, either alone or in combination. This was assumed in the following cases: neurological impairment of different origins (delirium, intoxication, metabolic coma, cerebral insults, elevated intracerebral pressure); respiratory failure with and without hypoxia; cardiogenic failure (including life-threatening arrhythmias); state of shock; severe sepsis; massive bleeding; acute renal failure; or other life-threatening organ dysfunctions.

Patients without any of the above mentioned indications for ICU treatment were transferred within 24 hours postoperatively to the intermediate care unit.

Statistical analysis
--------------------

Due to deviations from the normal distribution, all analyses were performed non-parametrically. Results were expressed as median, 25^th^to 75^th^percentiles and interquartile ranges. Mann-Whitney-U-test and Fisher\'s test were used for inter-group differences. Dichotomous variables were examined with the chi-squared test. In case of small samples, larger but unbalanced groups, data sets containing ties, or sparse data, tests were carried out in an exact version. We used a univariate logistic regression model (also exact) to identify parameters that were associated with a prolonged ICU treatment (response: \< 48 hours versus ≥ 48 hours). Data with regard to hepatic function and perfusion with respect to time were analysed using nonparametric multivariate analysis of variance for longitudinal data and small sample sizes in a two-factorial design (1^st^factor (prolonged ICU treatment: \< 48 hours versus ≥ 48 hours), 2^nd^factor (time)) \[[@B19]\]. Therefore, we compared all measurements simultaneously on the corresponding response curves. A *P*\< 0.05 was considered to be significant. All tests should be understood as constituting exploratory data analysis, such that no adjustments for multiple testing have been made. Numerical calculations were carried out with SPSS for WINDOWS, Release 14.1 (SPSS Inc, Chicago, IL, USA), LogXact-7 (Cytel Software Corp, Cambridge, MA, USA) and SAS 8.02 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Prediction of prolonged ICU treatment
-------------------------------------

Fifty-three patients were transferred from the ICU within 48 hours. The median ICU treatment in these patients was 22 (20 to 24) hours. Six patients underwent a prolonged ICU stay with a median duration of ICU treatment of 100 (64 to 107) hours. Causes of the prolonged ICU treatment were severe systemic inflammatory response syndrome with vasopressor treatment (n = 3, one patient died later from septic multiple-organ failure), prolonged mechanical ventilation due to severely compromised gas exchange (n = 1), cardiac failure (n = 3) and postoperative symptomatic transitory psychotic syndrome (n = 1). Haemodilutional anaemia did not differ between patients with and without prolonged ICU treatment (Figure [1b](#F1){ref-type="fig"}).

![Haemoglobin levels of different patient populations. **(a)**Haemoglobin levels of different groups of haemodilutional anaemia during the study period. red line: 25% hct group, orange line: 20% hct group. **(b)**Haemoglobin levels of patients with and without prolonged intensive care unit (ICU) treatment. blue line: patients with 48 hours or more ICU treatment, green line: patients with less than 48 hours ICU treatment. CPB = cardiopulmonary bypass.](cc8045-1){#F1}

Univariate analysis of *a priori*chosen parameters for prolonged ICU treatment showed that the group assignment for haemodilutional anaemia (*P*= 0.29), age (*P*= 0.48), BMI (*P*= 0.47), cardiac index after surgery (p~1\ h\ ITS~= 0.86; p~6\ h\ ITS~= 0.46 and p~18\ h\ ITS~= 0.31) and venous oxygen saturation after surgery (p~1\ h\ ITS~= 0.43; p~6\ h\ ITS~= 0.13 and p~18\ h\ ITS~= 0.21) did not influence the length of ICU treatment. Only the postoperative measurements of PDR ICG (p~1\ h\ ITS~\< 0.01; p~6\ h\ ITS~= 0.04 and p~18\ h\ ITS~\< 0.01) and ASAT (p~1\ h\ ITS~= 0.36; p~6\ h\ ITS~= 0.02 and p~18\ h\ ITS~= 0.01) were identified to influence the length of ICU treatment. Results of the logistic regression analysis of these selected parameters are provided in Table [1](#T1){ref-type="table"}.

###### 

Logistic regression of postoperative PDR ICG, ASAT and α-GST

  ------------------------------------------------------------------------------------------------------------------------
                                               Coeff. Beta   Lower 95% CI of Beta   Upper 95% CI of Beta   *P*value
  -------------------------------------------- ------------- ---------------------- ---------------------- ---------------
  **[1 hour after admission to ICU]{.ul}**                                                                 

                                                                                                           

  PDR ICG\                                     ***-0.55***   ***-1.04***            ***-0.21***            ***\< 0.01***
  (%/min)                                                                                                  

                                                                                                           

  ASAT\                                        0.02          -0.03                  0.06                   0.36
  (U/μl)                                                                                                   

                                                                                                           

  α-GST\                                       0.02          -0.01                  0.04                   0.18
  \[U/μl \]                                                                                                

                                                                                                           

  **[6 hours after admission to ICU]{.ul}**                                                                

                                                                                                           

  PDR ICG\                                     ***-0.25***   ***-0.55***            ***-0.01***            ***0.04***
  (%/min)                                                                                                  

                                                                                                           

  ASAT\                                        ***0.05***    ***0.01***             ***0.09***             ***0.02***
  (U/μl)                                                                                                   

                                                                                                           

  α-GST\                                       0.07          -0.01                  0.15                   0.07
  (U/μl)                                                                                                   

                                                                                                           

  **[18 hours after admission to ICU]{.ul}**                                                               

                                                                                                           

  PDR ICG\                                     ***-0.31***   ***-0.58***            ***-0.08***            ***\< 0.01***
  (%/min)                                                                                                  

                                                                                                           

  ASAT\                                        ***0.02***    ***0.01***             ***0.03***             ***0.01***
  (U/μl)                                                                                                   

                                                                                                           

  α-GST\                                       0.33          -0.39                  1.03                   0.35
  (U/μl)                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------

α-GST = α-glutathione S-transferase; ASAT = aspartate aminotransferase; CI = confidence interval; ICG = indocyanine green; ICU = intensive care unit; PDR = plasma-disappearance rate.

Multivariate longitudinal analysis showed that PDR of ICG and ASAT during the whole study period differed significantly between patients being transferred within 48 hours from ICU and patients that were treated longer than 48 hours on the ICU (Figure [2](#F2){ref-type="fig"}, *P*\< 0.01 for PDR ICG and *P*\< 0.01 for ASAT).

![PDR ICG, ASAT and α-GST of patients with (green bars) and without (blue bars) prolonged ICU treatment during the study period. α-GST = α-glutathione-S-transferase; ASAT = aspartate aminotransferase; PDR ICG = plasma disappearance rate of indocyanine green.](cc8045-2){#F2}

Influence of haemodilutional anaemia
------------------------------------

Baseline parameters did not differ between study groups of haemodilutional anaemia (Table [2](#T2){ref-type="table"}). The targeted level of haemodilutional anaemia was achieved in both study groups (Figure [1a](#F1){ref-type="fig"}). PDR of ICG as well as ASAT and α-GST did not differ between groups of haemodilutional anaemia (Figure [3](#F3){ref-type="fig"}). Surgery and ICU-related data are provided in Table [3](#T3){ref-type="table"}. There were no significant differences between both groups of haemodilutional anaemia. There were also no significant differences regarding haemodynamics between both groups of haemodilutional anaemia, except systemic vascular resistance one hour after admission to the ICU (Table [4](#T4){ref-type="table"}). Two patients in the 25% hct group versus no patient in the 20% hct group received an intra-aortal balloon pump for weaning from CPB. This, however, did not reach statistical significance.

![PDR ICG, ASAT and α-GST of the two groups of haemodilutional anaemia during the study period. red bars: haematocrit (Hct) of 25% during cardiopulmonary bypass (CPB). yellow bars: Hct of 20% during CPB. α-GST = α-glutathione-S-transferase; ASAT = aspartate aminotransferase; PDR ICG = plasma disappearance rate of indocyanine green.](cc8045-3){#F3}

###### 

Baseline characteristics

  -------------------------------------------------------------------------------------------------
                                  haematocrit 25%   haematocrit 20%   *P*value               
  ------------------------------- ----------------- ----------------- ---------- ----------- ------
  **Age**\                        60                54-69             64         58-68       0.40
  **(years)**                                                                                

                                                                                             

  **Gender**\                     26/4                                29/0                   
  **(m - male/f - female)**                                                                  

                                                                                             

  **Height**\                     1.76              1.72-1.80         1.75       1.72-1.79   0.81
  **(m)**                                                                                    

                                                                                             

  **Weight**\                     90                80-100            90         80-101      0.95
  **(kg)**                                                                                   

                                                                                             

  **body mass index**\            28.1              26.1-32.6         28.8       26.9-30.3   0.98
  **(kg/m^2^)**                                                                              

                                                                                             

  **preoperative haematocrit**\   41.7              40.1-43           42.2       39.3-45.8   0.72
  **(%)**                                                                                    
  -------------------------------------------------------------------------------------------------

IQR = interquartile range.

###### 

Intraoperative outcome measures

  ------------------------------------------------------------------------------------------------------------------------
                                                         haematocrit 25%   haematocrit 20%   *P*value               
  ------------------------------------------------------ ----------------- ----------------- ---------- ----------- ------
  **CI during CPB**\                                     3.2               3.0-3.6           3.2        3.0-3.5     0.40
  **(l/m**^2^**/min)**                                                                                              

                                                                                                                    

  **Temperature during CPB**\                            35.5              35.0-35.9         35.7       35.4-36.0   0.21
  **(°C)**                                                                                                          

                                                                                                                    

  **Cumulative norepinephrine-dosage during CPB (mg)**   0.06              0.04-0.09         0.05       0.02-0.09   0.41

                                                                                                                    

  **Urine volume during CPB**\                           148               80-250            150        86-177      0.94
  **(mL)**                                                                                                          

                                                                                                                    

  **duration of anaesthesia**\                           300               290-320           313        295-338     0.16
  **(min)**                                                                                                         

                                                                                                                    

  **duration of surgery**\                               200               160-220           203        175-243     0.21
  **(min)**                                                                                                         

                                                                                                                    

  **CPB time**\                                          74                52-83             71         63-81       0.72
  **(min)**                                                                                                         

                                                                                                                    

  **aortic cross clamp time**\                           45                32-58             44         38-49       0.81
  **(min)**                                                                                                         

                                                                                                                    

  **Length of ICU treatment**\                           22                20-24             23         21-27       0.29
  **(hours)**                                                                                                       

                                                                                                                    

  **Length of mechanical ventilation**\                  10                8-13              11         10-14       0.10
  **(hours)**                                                                                                       

                                                                                                                    

  **APACHE II score**                                    14                10-19             16         14-17       0.13
  ------------------------------------------------------------------------------------------------------------------------

APACHE = Acute Physiology and Chronic Health Evaluation; CI = cardiac index; CPB = cardiopulmonary bypass; Hct = haemotacrit; ICU = intensive care unit.

###### 

Haemodynamic measurements throughout the study period

                                               haematocrit 25%   haematocrit 20%   *P*value              
  -------------------------------------------- ----------------- ----------------- ---------- ---------- ------
  **[Before haemodilution]{.ul}**                                                                        
                                                                                                         
  MAP (mm Hg)                                  70                65-79             67         62-78      0.42
                                                                                                         
  CVP (mm Hg)                                  12                10-15             12         9-14       0.31
                                                                                                         
  CI (l/min/m^2^)                              2.2               1.9-2.5           2.1        1.9-2.4    0.39
                                                                                                         
  SVR (dyn/s/cm^-5^)                           1045              863-1264          1099       919-1286   0.47
                                                                                                         
  **[At the end of surgery]{.ul}**                                                                       
                                                                                                         
  MAP (mm Hg)                                  69                63-87             72         60-80      0.53
                                                                                                         
  CVP (mm Hg)                                  9                 6-12              11         9-14       0.13
                                                                                                         
  CI (l/min/m^2^)                              3.6               3.2-4.2           3.7        3.2-4.1    0.46
                                                                                                         
  SVR (dyn/s/cm^-5^)                           699               536-811           570        497-788    0.41
                                                                                                         
  **[1 hour after admission to ICU]{.ul}**                                                               
                                                                                                         
  MAP (mm Hg)                                  83                74-92             83         71-89      0.58
                                                                                                         
  CVP (mm Hg)                                  10                8-13              12         7-14       0.46
                                                                                                         
  CI (l/min/m^2^)                              3.0               2.6-3.4           3.2        2.8-3.7    0.24
                                                                                                         
  SVR (dyn/s/cm^-5^)                           952               792-1160          798        694-952    0.02
                                                                                                         
  **[6 hours after admission to ICU]{.ul}**                                                              
                                                                                                         
  MAP (mm Hg)                                  79                71-85             73         68-82      0.05
                                                                                                         
  CVP (mm Hg)                                  10                7-12              11         8-13       0.77
                                                                                                         
  CI (l/min/m^2^)                              3.1               2.6-3.6           3.0        2.6-3.6    0.74
                                                                                                         
  SVR (dyn/s/cm^-5^)                           870               719-1197          811        611-935    0.26
                                                                                                         
  **[18 hours after admission to ICU]{.ul}**                                                             
                                                                                                         
  MAP (mm Hg)                                  81                73-89             75         69-89      0.54
                                                                                                         
  CVP (mm Hg)                                  9                 5-13              9          8-11       0.63
                                                                                                         
  CI (l/min/m^2^)                              3.2               2.8-4.2           3.5        2.9-4.0    0.68
                                                                                                         
  SVR (dyn/s/cm^-5^)                           848               694-1022          754        629-963    0.61

CI = cardiac index; CVP = central venous pressure; ICU = intensive care unit; IQR = interquartile range; MAP = mean arterial pressure; SVR = systemic vascular resistance

Discussion
==========

The most important finding in this study is that the PDR of ICG was the only predictive parameter of prolonged ICU treatment. This was shown in a univariate logistic regression model and a multivariate longitudinal analysis, testing for possible confounders. The second major finding of our investigation was that haemodilutional anaemia during normothermic CPB to a Hct of 0.20 did not impair hepatic perfusion and function and had no impact on postoperative duration of ICU treatment.

Severe hepatic hypoperfusion and dysfunction after cardiac surgery is a rare but often fatal complication. However, mild hypoperfusion with increased hepatic oxygen extraction rate and redistribution of the global cardiac output to other organ systems than the hepatic system has been reported by several investigators \[[@B12],[@B20]\]. Therefore, it seems quite reasonable to monitor hepatic perfusion and function during and after cardiac surgery in the context of haemodilution during normothermic CPB, ICG has been proven by several studies to be a valid marker for liver function and perfusion \[[@B21],[@B22]\]. After intravenous injection, it is bound to plasma proteins and then exclusively eliminated by hepatocytes into the bile. Previous work has established that the PDR ICG is a valid marker of hepatic function and perfusion \[[@B23]-[@B25]\].

Haemodilution in this study did not significantly influence haemodynamics, outcome and hepatic function and perfusion parameters after normothermic CPB. Therefore, even under normothermic conditions a Hct of 20% during CPB might be considered safe with regard to functional parameters such as PDR ICG and structural integrity of the liver quantified by ASAT and α-GST. The effect of haemodilution on the perfusion of the hepatic region has been investigated previously. It was demonstrated in an animal study that a haemodilution to a Hct of 0.20 was associated with increased hepatic perfusion and increased ICG clearance \[[@B26],[@B27]\]. Later this was also shown after CABG surgery by the authors\' group and others \[[@B28]\]. In our study we found increased levels of ASAT and α-GST after surgery without any difference between groups of haemodilutional anaemia. Increased levels of both enzymes after cardiac surgery have been reported previously \[[@B13],[@B20]\].

Even if haemodilution was not found to be associated with hepatic perfusion and function abnormalities after CABG surgery with CPB in this study, some patients have been reported previously by others to developed postoperative hepatic hypoperfusion and dysfunction quantified by decreased postoperative PDR ICG during and after CABG surgery \[[@B12],[@B29]\]. Therefore, even independent from haemodilution during normothermic CPB, hepatic perfusion might be useful to monitor because it was shown previously that decreased PDR ICG might be of prognostic relevance in other settings \[[@B15],[@B23]\].

Sakka and colleagues concluded in his retrospective study in 336 critically ill patients that PDR ICG as a marker of hepatic perfusion and function is a good predictor of survival in critically ill patients: mortality increased with lower ICG-PDR values, and nonsurvivors had significantly lower ICG-PDR values than survivors \[[@B15]\]. Furthermore in a study in 21 critically ill patients it was concluded that the PDR ICG can identify reversible hepatic dysfunction in septic shock, suggesting good prognosis. Either failure to increase the PDR ICG within 120 hours or an extremely low PDR ICG was a poor prognostic sign \[[@B30]\].

In cardiac surgery, increased proinflammatory responses with an activation of immune cells like macrophages and granulocytes might be involved in postoperative hepatic dysfunction \[[@B31]\]. Keeping in mind that hepatic dysfunction and hypoperfusion was associated with worse outcome in an ICU setting, it seems convincing that early postoperative hepatic dysfunction indicated by a decreased ICG PDR might be associated with prolonged and complicated postoperative ICU treatment. This is in line with our finding that the PDR ICG on admission to the ICU was the best predictor of prolonged ICU treatment.

Evaluation of the plasma concentration of the ASAT has become clinical routine to estimate liver integrity. Cardiac surgery has been shown previously to increase ASAT concentration in the plasma \[[@B13]\]. Different authors concluded that the main reason for the increased ASAT liberation from the hepatocytes might be damage by the systemic inflammation process after CPB and transient hepatic hypoperfusion \[[@B32]\]. Nonetheless, as seen in our study, increases are seen late and are not specific for postoperative complications. This was also reported previously \[[@B33]\]. Another major shortcoming is that increased levels of liver enzymes can only indicate damage and are therefore not suitable to serve as an indication of the patients\' regional perfusion. A more sensitive parameter should indicate hepatic hypoperfusion that could be treated before damage to the liver occurs.

Clinically, the α-GST is used to assess postoperative liver damage and liver integrity after liver transplantation \[[@B34]\]. Again the main reason for the increased α-GST levels in the plasma is thought to occur due to systemic inflammation after CPB and transient hepatic hypoperfusion damaging the liver \[[@B32]\]. However, the α-GST, as other standard liver function tests are, is neither sensitive nor specific in the identification of patients with impaired hepatic function \[[@B13],[@B35]\]. Therefore, in a number of patients hepatic hypoperfusion and dysfunction might remain disguised for too long a time period. Significant elevations of α-GST or ASAT point to structural damage to the liver. Yet this is noticed very late after the onset of hepatic hypoperfusion. Thus, detection of elevated liver enzymes cannot be used to prevent damage to the hepatic system - it can only be used to limit damage. In contrast to this, the early determination of the PDR ICG might help to identify patients being at risk of hepatic hypoperfusion and dysfunction that could be treated before structural damage occurs. This would be in accordance to our finding that compared with other variables, an early postoperative decreased PDR ICG was predictive for complicated and prolonged postoperative ICU treatment.

A major limitation of our study is that we cannot provide a causal relationship between the decreased PDR ICG and the observed prolonged ICU treatment. However, this should be done by goal-directed study aiming at improving the PDR ICG in patients at risk of hepatic hypoperfusion after cardiac surgery. Another limitation is the rather small sample size of patients with prolonged ICU treatment. Therefore, the impact of the PDR ICG on outcome should be studied in a group of patients with higher perioperative risk for complications. In this study all patients received aprotinin as our standard antifibrinolytic therapy at that time. This was performed because the evidence of the potential deleterious effects of aprotinin was not published at the time at which this study was performed. Nevertheless, as all patients were treated with aprotinin this should not influence our results.

Conclusions
===========

In conclusion this study found evidence that impaired hepatic function and perfusion quantified by measurements of PDR ICG was an early marker of prolonged ICU treatment. Therefore, PDR ICG might serve as an early marker for compromised regional perfusion and goal-directed strategies aimed at improving the PDR ICG should be undertaken in cardiac surgical patients at risk to determine whether an outcome benefit exists. Furthermore, our study of patients undergoing different levels of haemodilutional anaemia investigating hepatic function and perfusion showed that we could not observe significant differences between hepatic function and perfusion quantified by measurements of PDR ICG, plasma levels of ASAT and α-GST. Therefore, haemodilution during CPB to 20% might be considered safe with regard to hepatic perfusion and function in patients with no pre-existing gastrointestinal diseases.

Key messages
============

• Our study showed that impaired PDR ICG as a marker of hepatic function and perfusion may be a valid marker of prolonged ICU treatment.

• Our study provides evidence that haemodilutional anaemia to a Hct of 20% does not impair hepatic function and perfusion.
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